Granted Patent
B2
US 12,186,364 · App. 17/691,610 · Granted Jan 7, 2025
Proteins for the treatment of epithelial barrier function disorders
Inventors:
Andrew Wonhee Han (Brisbane, CA); Andrew W. Goodyear (Brisbane, CA); Tarunmeet Gujral (Brisbane, CA); Todd Zachary DeSantis (Brisbane, CA); Karim Dabbagh (Brisbane, CA)
Assignee:
Genevive, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
Claims (3)
1. A pharmaceutical composition comprising a protein consisting of the amino acid sequence of SEQ ID NO: 5; and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , formulated for rectal, parenteral, intravenous, topical, oral, dermal, transdermal, or subcutaneous administration.
3. The pharmaceutical composition of claim 1 , formulated such that the protein has activity in the gastrointestinal lumen and/or intestines of the patient.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2024
From: SECOND GENOME, INC.
To: GENEVIVE, INC.
Reel/Frame 065994/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 5, 2022
From: HAN, ANDREW WONHEE; GOODYEAR, ANDREW W.; GUJRAL, TARUNMEET; DESANTIS, TODD ZACHARY; DABBAGH, KARIM
To: SECOND GENOME, INC.
Reel/Frame 059826/0081 →
Continuity (3)
Division
16610823
Provisional Application
62501231
· May 4, 2017
References Cited (117)
US 4399216A
· Axel
· 1983
[cited by applicant]
US 5767063A
· Lee
· 1998
[cited by applicant]
US 20020052336A1
· Yerxa
· 2002
[cited by examiner]
US 20050100531A1
· Bienenstock
· 2005
[cited by applicant]
US 20080311097A1
· Israelsen
· 2008
[cited by examiner]
WO WO2016141108
· 2016
[cited by applicant]
WO WO2018204757
· 2018
[cited by applicant]
UniProtKB Accession No. A0A1C5XCW0 (A0A1C5XCW0_9FIRM) uncultured
[cited by examiner]
UniProtKB Accession No. A0A1C5XCW0 (A0A1C5XCW0_9FIRM) uncultured
[cited by examiner]
Pajon et al. The genome sequence of Coprococcus catus GD/7. Submitted (Mar. 2010) to and published in the EMBL/GenBank/DDBJ databases.
[cited by examiner]
Altschul et al., “Basic local alignment search tool.”, J. MoL Biol. Oct. 1990, 215: 3, 403-410.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. Sep. 1997, 25(17): 3389-3402.
[cited by applicant]
Antonsson and Persson, “Induction of Apoptosis by Staurosporine Involves the Inhibition of Expression of the Major Cell Cycle Proteins at the G2/M Checkpoint Accompanied by Alterations in Erk and Akt Kinase Activities”,…
[cited by applicant]
Aroniadis et al., “Fecal Microbiota Transplantation: past, present and future.”, Curr. Opin. Gastroenterol. Jan.y 2013, 29 (1), 79-84.
[cited by applicant]
Autm, www.atum.bio/services/genegps, “GPS Technology”, 5 pages, retrieved from Internet Jun. 17, 2020.
[cited by applicant]
Ayoubi et al., “Regulation of gene expression by alternative promoters.”, FASEB J. Mar. 1996, 10, 453-460.
[cited by applicant]
Baron et al., “Variation Between Observers in Describing Mucosal Appearances in Proctocolitis”, BMJ, 1: 89, 4 pages, 1964.
[cited by applicant]
Béduneau et al., “A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.”, Eur J Phann Biopharm, 87: 290-298, 2014.
[cited by applicant]
Berge et al., “Pharmaceutical Salts”, J. Pharm Sci. 66: 2, 19 pages, 1977.
[cited by applicant]
Berger et al., “Oleic Acid Uptake Reveals the Rescued Enterocyte Phenotype of Colon Cancer Caco-2 by HT29-MTX Cells in Co-Culture Mode”, Int J Mol Sci, 18: 1573, 21 pages, 2017.
[cited by applicant]
Best et al., “Development of a Crohn's disease activity index.”, National Cooperative Crolm's Disease Study, Gastroenterol. 70: 439-444, 1976.
[cited by applicant]
Bibiloni et al., “VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.”, Am J Gastroenterol, 100: 1539-1546, 2005.
[cited by applicant]
Blackstone, “Inflammatory bowel disease,” In: Blackstone MO (ed.) Endoscopic interpretation: normal and pathologic appearances of the gastrointestinal tract, 1984, pp. 464-494.
[cited by applicant]
Boltin et al., “Mucin Function in Inflammatory Bowel Disease: An Update”, J. Clin. GastroenteroL 47(2): 106-111, 2013.
[cited by applicant]
Botoman et al., “Management of Inflammatory Bowel Disease”, Am. Fam. Physician, vol. 57(1): 57-68, 1998.
[cited by applicant]
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science 247: 1306-1310, 1990.
[cited by applicant]
Bratt et al., “A phase 1 tri.al with transgenic bacteria expressing interleukin-10 in Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 4, pp. 754-759, 2006.
[cited by applicant]
Cani et al., “Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice”, Diabetes, vol. 57, pp. 1470-1481, 2008.
[cited by applicant]
Chassaign et al., “Dextran sulfate sodium(DSS)-induced colitis in mice,” Curr Protoc Imunol, 2014, 104:15.25.
[cited by applicant]
Danese et al., “Etiopathogenesis of inflammatory bowel diseases”, World J. GastroenteroL 12: 4807-4812, 2006.
[cited by applicant]
Daperno et al., “Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.”, J Crohns Cohtis., 5: 4…
[cited by applicant]
Delzenne et al., “Targeting gut microbiota in obesity: effects of prebiotics and probiotics,” Nature Reviews, vol. 7, pp. 639-646, 2011.
[cited by applicant]
Dewi et al., “In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection”, Journal of Virological Methods, 121: 171-180, 2004.
[cited by applicant]
Dewi et al., “Peripheral blood mononuclear cells increase the permeability of dengue virus-infected endothelial cells in association with downregulation of vascular endothelial cadherin”, J. Gen. Virol. 89: 642-652, 200…
[cited by applicant]
Duncan et al., “Proposal of
[cited by applicant]
Durrer and Allen, “Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU”, PLoS One, 12: e0176286, 17 pages, 2017.
[cited by applicant]
Everard et al., “Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity”, PNAS, vol. 110, No. 22, pp. 9066-9071, 2013.
[cited by applicant]
Everard et al., “Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice”, Diabetes, vol. 60, pp. 2775-2786, 2011.
[cited by applicant]
Gassier et al.., “Inflammatory bowel disease is associated with changes of enterocytic junctions.”, Am J Physiol Gastrointest Liver Physiol., 281: G216-G228, 2001.
[cited by applicant]
Gaston et al., “S-Nitrosylation Signaling in Cell Biology”, Mol Interv. 3, 253-263, 2003.
[cited by applicant]
GenScript: www.genscript.com/codon-opt.html, “OptimumGene-Codon Optimization”, 5 pages.
[cited by applicant]
Glozak et al., “Acetylation and deacetylation of non-histone proteins.”, Gene. 363, 15-23, 2005.
[cited by applicant]
Han et al., “Detergent-free biotin switch combined with liquid chromatography/tandem mass spectrometry in the analysis of S-nitrosylated proteins.”, Rapid Commun Mass Spectrom. 22, 1137-1145, 2008.
[cited by applicant]
Hanniffy et al., “Mucosal Delivery of a Pneumococcal Vaccine Using Lactococcus lactis Affords Protection against Respiratory Infection” Journal ofinfectious Diseases, vol. 195, pp. 185-193, 2007.
[cited by applicant]
Harvey et al., “A simple index of Crohn's-disease activity”, Lancet 1(8178): 1134-1135, 1980.
[cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci. 89(22): 10915-10919, 1992.
[cited by applicant]
Higgins et al., “Clustal: a package for performing multiple sequence alignment on a microcomputer”, Gene 73: 237-244, 1998.
[cited by applicant]
Horhota et al., “Glycerol Nucleoside Triphosphates: Synthesis and Polymerase Substrate Activities”, Organic Letters 8: 5345-5347, 2006.
[cited by applicant]
Hsiao et al., “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci. (USA), 76: 3829-3833, 1979.
[cited by applicant]
Huynh et al., “Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.”, Inflamm Bowel Dis., 15: 760-768, 2009.
[cited by applicant]
Imai et al., “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase”, Nature. 403, 795-800, 2000.
[cited by applicant]
Integrated DNA Technologies: https://www.idtdna.com/pages/tools/codon-optimization-tool, “Synthetic gene design made easy”, 4 pages, 2020.
[cited by applicant]
International Human Genome Sequencing Consortium, “Finishing the euchromatic sequence of the human genome.”, Nature, 431, 931-45, 2004.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No.PCT/US2018/031046, dated Sep. 13, 2018, 8 pages.
[cited by applicant]
Irvine et al., “Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease”, Gastroenterology 106: 287-296, 1994.
[cited by applicant]
IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) and IUPAC-HJB Commission on Biochemical Nomenclature (CBN), Nomendature of aAmino Acids, (Recommendations 1974), Biochemistry 14: 449-462, 1975.
[cited by applicant]
Jaffrey et al., “The Biotin Switch Method for the Detection of S-Nitrosylated Proteins”, Sci STKE., 10 pages, 2001.
[cited by applicant]
Jensen, “Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry”, Curr Opin Chem Biol. 8, 33-41, 2004.
[cited by applicant]
Johansson et al., “Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis”, Gut 63: 281-291, 2014.
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc, Natl. Acad. Sci, 90: 5873-5877, 1993.
[cited by applicant]
Kiesler et al., “Experimental Models of Inflammatory Bowel Diseases.”, Cell Mol Gastroenterol Hepatol, 1(2): 154-170, 2015.
[cited by applicant]
Kim et al., “Investigating Intestinal Inflammation in DSS-induced Model of IBD” Journal of Visualized Experiments, vol. 60., pp. 2-6, 2012.
[cited by applicant]
Kyte and Doolittle, “A Simple Method for Displaying the Hydropathic Character of a Protein”, J. Mol. Biol. 157: 105-132, 1982.
[cited by applicant]
Lerner et al., “Dysbiosis May Trigger Autoimmune Diseases via Inappropriate Post-Translational Modification of Host Proteins”, Frontiers in Microbiology, vol. 7, Article 84, 2016.
[cited by applicant]
Levesque et al., “Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.”, Gastroenterology, 148: 37-51, 2015.
[cited by applicant]
Machiels et al., “A decrease of the butyrate-producing species
[cited by applicant]
Maloy et al., “Intestinal homeostasis and its breakdown in inflammatory bowel disease”, Nature. 474 (73:51): 298-306, 2011.
[cited by applicant]
Mandic et al., “Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay.”, Clin. Exp. Metast. 21: 699-704, 2004.
[cited by applicant]
Mansour et al., “Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes”, Nature, 336: 348-352, 1988.
[cited by applicant]
Matts, “The value of rectal biopsy in the diagnosis of ulcerative colitis.”, QJM, 30: 393-407, 1961.
[cited by applicant]
Merrifield, “Solid phase peptide synthesis I. The synthesis of a tetrapeptide,” Am. Chem. Soc., 8.5: 2149-2154, 1963.
[cited by applicant]
Moayyedi et al., “Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.”, Gastroenterology, 149: 102-109, e106, 2015.
[cited by applicant]
Molodecky et al., “Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review”, Gastroenterol 142: 46-54, 2012.
[cited by applicant]
Myers et al., “Optimal alignments in linear space”, CABIOS 4: 11-17, 1988.
[cited by applicant]
Narula et al., “Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis”, Inflamm Bowel Dis., 23(10): 1702-1709, 2017.
[cited by applicant]
Needleman et al., “A general method applicable to the search fix similarities in the amino acid sequence of two proteins”, J. MoL Biol., 48(3): 444-453, 1970.
[cited by applicant]
Neurath, “Cytokines in inflammatory bowel disease”, Nature Reviews Immunology, vol. 14., 329-342, 2014.
[cited by applicant]
Paine, “Colonoscopic evaluation in ulcerative colitis.”, Gastroenterol Rep 2: 161-168, 2014.
[cited by applicant]
Pajoe et al., “ The genome sequence of coproccus catus GD/7,” EMBL/GenBank/DDBJ, Mar. 2010.
[cited by applicant]
Pan et al., “Oral administration of Lactobacillus paracasei alleviates clinical symptoms of colitis induced by dextran sulphate sodium salt in BALB/c mice”, Beneficial Microbes, 5: 315-322, 2014.
[cited by applicant]
Patterson et al., “Human Gut Symbiont Roseburia hominis Promotes and Regulates Innate Immunity.”, Front Immunol 8: 1166, 14 pages, 2017.
[cited by applicant]
PCT International Search Report and Written Opinion in Internnational Appln No. PCT/US18/31046, dated Sep. 13, 2018, 13 pages.
[cited by applicant]
Person et al., 1988, Improved tools for biological sequence comparison, Proc. Natl. Acad. ScL 85: 2444-2448.
[cited by applicant]
Plovier et al., “A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice”, Nat Med, 23: 107-113, 2017.
[cited by applicant]
Qazi et al., “The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis”, Gut Microbes, 8: 574-588, 2017.
[cited by applicant]
Rachmilewitz, “Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.”, BMJ, 298: 82-86, 1989.
[cited by applicant]
Sands et al., “Infliximab Maintenance Therapy for Fistulizing Crohn's Disease”, N Eng J Med 350 (9): 876-885, 2004.
[cited by applicant]
Sands, “From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation”, Gastroenterology 126: 1518-1532, 2004.
[cited by applicant]
Schroeder et al., “Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.”, N Eng J Med., 317: 1625-1629, 1987.
[cited by applicant]
Shawki and McCole, “Mechanisms of Intestinal Epithelial Barrier Dysfunction by Adherent-Invasive
[cited by applicant]
Sheth et al., “Manipulating Bacterial Communities by in Situ Microbiome Engineering” Trends in Genetics, vol. 32, Issue 4, pp. 189-200, 2016.
[cited by applicant]
Shigemori et al., “Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice” Microbial Cell Factories, vol. 14: 189, 12 pages, 2015.
[cited by applicant]
Simmonds et al., “Paneth cell metaplasia in newly diagnosed inflammatory bowel disease in children”, BMC GastroenteroL 14: 93, 6 pages, 2014.
[cited by applicant]
Srinivasan et al., “TEER measurement techniques for in vitro barrier model systems.”, J Lab Autom, 20: 107-126, 2015.
[cited by applicant]
Srutkova et al., “Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner”, PLoS One, 10: e0134050, 20 pages, 2015.
[cited by applicant]
Steidler et al., “Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10” Science, vol. 289, pp. 052-1355, 2000.
[cited by applicant]
Strober et al., “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases”, Gastroenterology, 140 (6): 1756-1767, 2011.
[cited by applicant]
Sutherland et al., “5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis,” Gastroenterology, 1987, 92:1894-1998.
[cited by applicant]
ThermoFisher: www.thermofisher.com/us/en/home/lifo-science/cloning/genesynthesis/geneart-gene-synthesis/geneoptimizerhtm, “Invitrogen GeneArt Gene Synthesis”, 4 pages, 2017.
[cited by applicant]
Thia et al., “Measurement of Disease Activity in Ulcerative Colitis: Interobserver Agreement and Predictors of Severity”, Inflamm Bowel Dis, 17: 1257-1264, 2011.
[cited by applicant]
Travis et al., “Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)”, Gut, 61: 535-542. 2012.
[cited by applicant]
Ulcerative Colitis: Introduction Johns Hopkins Medicine, found at: www.hopkinsmedicine.org/gastroenterology_ hepato logy/ _pdfs/small_largeintestine/ulcerativecolitis.pdf, 14 pages, 2013.
[cited by applicant]
UniProtKB Accession No. A0A1C5XCWO, “Uncultured
[cited by applicant]
UniProtKB Acession No. D4JA58, “Coprococcus catus GD/7, uncharacterized protein,” May 18, 2010, 3 pages.
[cited by applicant]
UniProtKB Acession No. K1U1P5, “human gut metagenome, uncharacterized protein,” Nov. 28, 2012, 2 pages.
[cited by applicant]
Van Solingen et al., “Fusion of Yeast Spheroplasts”, I. Bact, 130: 946-947, 1977.
[cited by applicant]
Vandenbroucke et al., “Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice”, Gastroenterology, vol. 127, pp. 502-513, 2004.
[cited by applicant]
Yan et al., “Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism”, J Clin Invest, 121: 2242-2253, 2011.
[cited by applicant]
Yang et al., “Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications.”, Mo] Cell. 31, 449-61, 2008.
[cited by applicant]
Zhang et al., “Cytokines, Inflammation and Pain”, Int. Anesthesiol. Clin. 45(2): 27-37, 2007.
[cited by applicant]
Zolotarevsky et al., “A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease.”, Gastroenterology, 123: 163-172, 2002.
[cited by applicant]